325 related articles for article (PubMed ID: 26050947)
1. FDG in Urologic Malignancies.
Høilund-Carlsen PF; Poulsen MH; Petersen H; Hess S; Lund L
PET Clin; 2014 Oct; 9(4):457-68, vi. PubMed ID: 26050947
[TBL] [Abstract][Full Text] [Related]
2. Possible role of FDG-PET in the evaluation of urologic malignancies.
Bender H; Schomburg A; Albers P; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1655-60. PubMed ID: 9179213
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
4. PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
Bouchelouche K; Choyke PL
PET Clin; 2015 Jul; 10(3):361-74. PubMed ID: 26099672
[TBL] [Abstract][Full Text] [Related]
5. Update on advances in molecular PET in urological oncology.
Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
[TBL] [Abstract][Full Text] [Related]
6. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in urological cancers].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S80-7. PubMed ID: 12739339
[No Abstract] [Full Text] [Related]
7. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
[TBL] [Abstract][Full Text] [Related]
9. The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers.
Avril N; Dambha F; Murray I; Shamash J; Powles T; Sahdev A
Int J Urol; 2010 Jun; 17(6):501-11. PubMed ID: 20370848
[TBL] [Abstract][Full Text] [Related]
10. Dual phase 18F-fluorodeoxyglucose positron emission tomography/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer.
Yildirim-Poyraz N; Ozdemir E; Uzun B; Turkolmez S
Rev Esp Med Nucl Imagen Mol; 2013; 32(4):214-21. PubMed ID: 23218514
[TBL] [Abstract][Full Text] [Related]
11. PET in prostate and bladder tumors.
Lee ST; Lawrentschuk N; Scott AM
Semin Nucl Med; 2012 Jul; 42(4):231-46. PubMed ID: 22681672
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review.
Bouchelouche K; Oehr P
J Urol; 2008 Jan; 179(1):34-45. PubMed ID: 17997425
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]Fluorodeoxyglucose - positron emission tomography/computed tomography improves staging in patients with high-risk muscle-invasive bladder cancer scheduled for radical cystectomy.
Kollberg P; Almquist H; Bläckberg M; Cronberg C; Garpered S; Gudjonsson S; Kleist J; Lyttkens K; Patschan O; Liedberg F
Scand J Urol; 2015; 49(4):296-301. PubMed ID: 25623843
[TBL] [Abstract][Full Text] [Related]
14. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
[TBL] [Abstract][Full Text] [Related]
16. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
[TBL] [Abstract][Full Text] [Related]
17. Urinary bladder leiomyosarcoma: staging with 18F-FDG PET/CT.
Makis W; Rakheja R; Nahal A; Hickeson M; Lisbona R
Clin Nucl Med; 2013 May; 38(5):e218-22. PubMed ID: 23377410
[TBL] [Abstract][Full Text] [Related]
18. Lymph node metastasis diagnosis using positron emission tomography with 2-[18F] fluoro-2-deoxy-D-glucose as a tracer and computed tomography in surgical cases of non-small cell lung cancer.
Ose N; Sawabata N; Minami M; Inoue M; Shintani Y; Kadota Y; Okumura M
Eur J Cardiothorac Surg; 2012 Jul; 42(1):89-92. PubMed ID: 22290887
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography in uro-oncology.
Hain SF
Cancer Imaging; 2005 Jan; 5(1):1-7. PubMed ID: 16154810
[TBL] [Abstract][Full Text] [Related]
20. [Value of computer tomography in staging urological tumors before radical surgery].
Romics I; Will C; Beutler W; Bach D
Orv Hetil; 1991 Dec; 132(50):2779-81. PubMed ID: 1823099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
